Trial title not recorded
Hypertension · Impaired Glucose Tolerance
Enrolment: 24 · Results not recorded
Loading the evidence…
Drug · Type-1 angiotensin II receptor antagonist (ANTAGONIST)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Hypertension · Impaired Glucose Tolerance
Enrolment: 24 · Results not recorded
Liver Transplant Recipients
Enrolment: 62 · Results not recorded
Proteinuria
Enrolment: 306 · Results not recorded
Hypertension
Enrolment: 122 · Results not recorded
Hypertension · Left Ventricular Hypertrophy
Enrolment: 90 · Results not recorded
Sarcopenia
Enrolment: 37 · Results not recorded
Hypertension · Adult Solid Tumor
Enrolment: 6 · Results not recorded
Femoroacetabular Impingement
Enrolment: 68 · Results not recorded
Healthy
Enrolment: 80 · Results not recorded
Healthy
Enrolment: 17 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Lipopolysaccharide-induced acute lung injury
Losartan significantly reduced the lipopolysaccharide-induced rise in bronchoalveolar lavage TNF-alpha and protein, lung myeloperoxidase activity, pulmonary oedema and lung injury score, and lowered LOX-1 mRNA and protein along with the LOX-1 mediated increases in caspase-3 and ICAM-1.
Extraction: extract · Supplied extraction confidence: 0.82. Machine-extracted fields require source verification.
Model: Right nephrectomy with 40 min clamping of the left renal artery followed by 24 h reperfusion, giving ischaemic acute renal failure
Losartan increased creatinine and urea clearance and HDL, reduced plasma lipid peroxidation, increased erythrocyte catalase, reduced cortico-medullary necrosis and tubular dilatation, and downregulated Bax.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.